Jean Hoffman-Censits

Assistant Professor

20082018
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Jean Hoffman-Censits is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 5 Similar Profiles
Urinary Bladder Neoplasms Medicine & Life Sciences
Prostatic Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Carcinoma Medicine & Life Sciences
Cisplatin Medicine & Life Sciences
Castration Medicine & Life Sciences
Muscles Medicine & Life Sciences
Platinum Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2008 2018

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)

Rosenberg, J. E., Hahn, N., Regan, M. M., Werner, L., Alva, A., George, S., Picus, J., Alter, R., Balar, A., Hoffman-Censits, J., Grivas, P., Lauer, R., Guancial, E. A., Hoimes, C., Sonpavde, G., Albany, C., Stein, M. N., Breen, T., Jacobs, C., Anderson, K. & 4 others, Bellmunt, J., Lalani, A. K. A., Pal, S. & Choueiri, T. K., May 16 2018, (Accepted/In press) In : British Journal of Cancer. p. 1-8 8 p.

Research output: Contribution to journalArticle

docetaxel
Platinum
Carcinoma
Survival
Antisense Oligonucleotides

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States

Pal, S. K., Hoffman-Censits, J., Zheng, H., Kaiser, C., Tayama, D. & Bellmunt, J., May 1 2018, In : European Urology. 73, 5, p. 800-806 7 p.

Research output: Contribution to journalArticle

Platinum
Carcinoma
MPDL3280A
Safety
Therapeutics

Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study

Myers, R. E., Leader, A. E., Hoffman-Censits, J., Trabulsi, E. J., Keith, S. W., Petrich, A. M., Quinn, A. M., Den, R. B., Hurwitz, M. D., Lallas, C. D., Hegarty, S. E., Dicker, A. P., Zeigler-Johnson, C. M., Giri, V. N., Ayaz, H. & Gomella, L. G., Feb 1 2018, In : Journal of Cancer Education. 33, 1, p. 180-185 6 p.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Decision Making
Therapeutics
Ambulatory Care
Nurses

Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations

Pal, S. K., Rosenberg, J. E., Hoffman-Censits, J., Berger, R., Quinn, D. I., Galsky, M. D., Wolf, J., Dittrich, C., Keam, B., Delord, J. P., Schellens, J. H. M., Gravis, G., Medioni, J., Maroto, P., Sriuranpong, V., Charoentum, C., Burris, H. A., Grünwald, V., Petrylak, D., Vaishampayan, U. & 15 others, Gez, E., De Giorgi, U., Lee, J. L., Voortman, J., Gupta, S., Sharma, S., Mortazavi, A., Vaughn, D. J., Isaacs, R., Parker, K., Chen, X., Yu, K., Porter, D., Porta, D. G. & Bajorin, D. F., Jul 1 2018, In : Cancer Discovery. 8, 7, p. 812-821 10 p.

Research output: Contribution to journalArticle

Fibroblast Growth Factor Receptors
Carcinoma
Hyperphosphatemia
Appetite
Constipation

First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy

Valicenti, R. K., Pugh, S. L., Trabulsi, E. J., Sartor, O., Ko, E. C., Girvigian, M. R., Rosenthal, S. A., Shaves, M. E., Hoffman-Censits, J., Schallenkamp, J. & Sandler, H. M., Mar 1 2018, In : International Journal of Radiation Oncology Biology Physics. 100, 3, p. 695-701 7 p.

Research output: Contribution to journalArticle

Samarium
Radiation Oncology
samarium
antigens
Prostate-Specific Antigen